Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

被引:4253
作者
Freeman, GJ
Long, AJ
Iwai, Y
Bourque, K
Chernova, T
Nishimura, H
Fitz, LJ
Malenkovich, N
Okazaki, T
Byrne, MC
Horton, HF
Fouser, L
Carter, L
Ling, V
Bowman, MR
Carreno, BM
Collins, M
Wood, CR
Honjo, T [1 ]
机构
[1] Kyoto Univ, Dept Med Chem, Grad Sch Med, Kyoto 6068501, Japan
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[3] Wyeth Ayerst Res, Inst Genet, Cambridge, MA 02140 USA
关键词
binding; proliferation inhibition; cytokine secretion inhibition; tissue expression; peripheral tolerance;
D O I
10.1084/jem.192.7.1027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of PD-1 (PD-LI) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 leads to the inhibition of T cell rcceptor-mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon gamma, and activated human and murine dendritic cells. In addition, PD-L1 is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently determine the extent of immune responses at sites of inflammation.
引用
收藏
页码:1027 / 1034
页数:8
相关论文
共 28 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]  
Blair PJ, 1998, J IMMUNOL, V160, P12
[3]   The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response [J].
Boussiotis, VA ;
Freeman, GJ ;
Gribben, JG ;
Nadler, LM .
IMMUNOLOGICAL REVIEWS, 1996, 153 :5-26
[4]  
BYRNE MC, 2000, CURRENT PROTOCOLS MO, V49
[5]  
Dong HD, 1999, NAT MED, V5, P1365
[6]   Characterization of murine Flt4 ligand VEGF-C [J].
Fitz, LJ ;
Morris, JC ;
Towler, P ;
Long, A ;
Burgess, P ;
Greco, R ;
Wang, J ;
Gassaway, R ;
Nickbarg, E ;
Kovacic, S ;
Ciarletta, A ;
Giannotti, J ;
Finnerty, H ;
Zollner, R ;
Beier, DR ;
Leak, LV ;
Turner, KJ ;
Wood, CR .
ONCOGENE, 1997, 15 (05) :613-618
[7]   SELECTIVE INDUCTION OF B7/BB-1 ON INTERFERON-GAMMA STIMULATED MONOCYTES - A POTENTIAL MECHANISM FOR AMPLIFICATION OF T-CELL ACTIVATION THROUGH THE CD28 PATHWAY [J].
FREEDMAN, AS ;
FREEMAN, GJ ;
RHYNHART, K ;
NADLER, LM .
CELLULAR IMMUNOLOGY, 1991, 137 (02) :429-437
[8]  
Freeman GJ, 1998, J IMMUNOL, V161, P2708
[9]  
FREEMAN GJ, 1992, J IMMUNOL, V149, P3795
[10]  
HARPER K, 1991, J IMMUNOL, V147, P1037